Boundless Bio Inc (BOLD)
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies that target extrachromosomal DNA, or ecDNA, for patients with oncogene-amplified cancers. Its lead candidate, BBI-940, is an ecDNA-directed therapeutic being evaluated in a Phase 1/2 trial in patients with estrogen receptor positive, HER2-negative breast cancer, as well as triple-negative breast cancer with a luminal androgen receptor subtype. The company was incorporated in 2018, changed its name from Pretzel Therapeutics, Inc. in July 2019, and is headquartered in San Diego, California. Boundless Bio’s common stock trades on the NASDAQ under the symbol BOLD.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BOLD
|
$3.36
|
19.6% Upside
|
Undervalued
|
$4
|
42.3% Upside
|
Undervalued
|
Good
|
0.0%
|
November 5, 2026
|
1.0x
|
63.918 M
|
-8.708 M
|
0.0%
|
70.7%
|
-1.1
|
88.6%
|
